Skip to search formSkip to main contentSkip to account menu

irinotecan

Known as: (+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate, Irrinotecan, (+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione 
A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Irinotecan, a… 
National Institutes of Health

Related topics

Related topics

35 relations
10 ML irinotecan hydrochloride liposome 4.3 MG/ML Injection [Onivyde]7-ethyl-10-hydroxycamptothecinApoptosisCYP3A7 protein, human

Broader (6)

Antineoplastic AgentsAntineoplastic Agents, PhytogenicCamptothecinEnzyme Inhibitors

Narrower (2)

CamptosarNK012 compound

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude Mice
Purpose: Anaplastic thyroid carcinoma (ATC) remains one of the most lethal known human cancers. Targeted molecular therapy with… 
Review
2004
Review
2004
Multiple management modalities in esophageal cancer: combined modality management approaches.
The overall success rate nationally in treating esophageal carcinomas remains poor, with over 90% of patients succumbing to the… 
Highly Cited
2004
Highly Cited
2004
Combined Irinotecan and Oxaliplatin in Patients with Advanced Pre-Treated Pancreatic Cancer
Objectives: This study evaluated the clinical activity and toxicity of combination chemotherapy with irinotecan and oxaliplatin… 
Highly Cited
2004
Highly Cited
2004
Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803)
3500 Background: Irinotecan prolongs survival in second line 5FU-refractory metastatic colorectal cancer (MCRC). First line… 
Review
2003
Review
2003
Theanine and glutamate transporter inhibitors enhance the antitumor efficacy of chemotherapeutic agents.
Highly Cited
2003
Highly Cited
2003
Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer.
PURPOSE To identify the maximum-tolerated dose and dose-limiting toxicity (DLT) of weekly irinotecan combined with cisplatin and… 
Highly Cited
2002
Highly Cited
2002
Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.
PURPOSE This phase II, multicenter, open-label, single-arm study evaluated the efficacy and safety of irinotecan and gemcitabine… 
Review
2002
Review
2002
Systemic treatment of colorectal cancer.
Review
2001
Review
2001
The evolution of fluoropyrimidine therapy: from intravenous to oral.
Chemotherapy for advanced colorectal cancer is based on i.v. 5-fluorouracil (5-FU). Numerous attempts have been made to increase… 
Highly Cited
1999
Highly Cited
1999
Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
PURPOSE To evaluate the efficacy and tolerance of combined irinotecan and oxaliplatin in patients with advanced colorectal cancer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)